Morgan Stanley Maintains Overweight on Inspire Medical Systems, Lowers Price Target to $210
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Kallum Titchmarsh maintains an Overweight rating on Inspire Medical Systems (NYSE:INSP) but lowers the price target from $250 to $210.

July 15, 2024 | 5:05 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Morgan Stanley maintains an Overweight rating on Inspire Medical Systems but lowers the price target from $250 to $210.
The Overweight rating suggests a positive outlook, but the lowered price target indicates some concerns or adjustments in valuation. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100